LTEP-a2 人肺腺癌細(xì)胞
Catalogue No.: C1316
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

both patients with advanced pklanoma and those with advanced NSCLC. In patients with advanced pklanoma, both PD-1 inhibitors (nivolumab and pembrolizumab) have shown improved survival versus ipilimumab. PD-1 inhibitors are associated with adverse events that have immune